ReviewJournal of clinical medicine2021
Paracetamol: A Review of Guideline Recommendations.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it, 187 citations in OpenAlex.
- [Clinical practice guideline for perioperative pain management in pediatric low-temperature plasma tonsillectomy].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2026Guideline
- Trial
- The effect of preemptive intravenous paracetamol-mannitol on postoperative analgesia and quality of recovery in elderly patients undergoing total hip arthroplasty.BMC anesthesiology · 2026Trial
- Pharmacokinetic profile of novel multi-layer stable effervescent tablet: a cross-over study with an established European brand in healthy young male adults.BMC pharmacology & toxicology · 2024Trial
- Paracetamol: A History of Assumptions, Errors, and Evidence Reversals in Pain Management.Current pain and headache reports · 2026Review
- [Pharmacological management of pain in chronic wounds and stomas in adult patients].Revista medica del Instituto Mexicano del Seguro Social · 2026Review
- Analgesic Prescribing Trends of Opioids, Nonsteroidal Anti-Inflammatory Drugs, and Paracetamol in Taiwan (2001-2020): Age-Period-Cohort Cross-Sectional Study.JMIR public health and surveillance · 2026Article
- Ultra-deformable transethosomal vesicle for enhancing transdermal delivery of NSAIDs: a comprehensive review.Inflammopharmacology · 2026Review
- Metal nanocrystals and nanoclusters with paracetamol passivation and for paracetamol detection: a critical review.Nanoscale advances · 2026Review
- Investigation of the Effects of Artemisinin on Acetaminophen-Induced Acute Liver Toxicity.Chemical research in toxicology · 2026Article
- FDA-Approved Drugs Containing Amide Functionality in the Last Five Years (2021-2025): Pharmaceutical Use, Trends and Synthetic Approaches.Medicines (Basel, Switzerland) · 2026Review
- Intravenous paracetamol does not have significant opioid-sparing effects when used as part of a multimodal analgesic protocol in dogs undergoing elective orthopaedic surgery.The Veterinary record · 2026Article
- Management of Mild to Moderate Pain from Triage to Discharge in the Emergency Department: A Multidisciplinary Delphi Consensus from the Italian Society of Emergency Medicine (SIMEU).Journal of clinical medicine · 2026Article
- Pain Management in Patient-Facing Pharmacy Settings in Jordan: Pharmacists' Knowledge, Attitudes, and Practices.Pain research & management · 2026Article
- The impact of patient age on the pharmacist's recommendation of OTC anti-common cold products before and during the COVID-19 pandemic.Frontiers in pharmacology · 2026Article
- The interaction between paracetamol and ethanol during the early development of zebrafish.Frontiers in pharmacology · 2026Article
- Self-Management Strategies for Treating Pediatric and Adolescent Headaches and Migraines with Over-the-Counter Molecules: Expert Opinion and Literature Review.Pain and therapy · 2025Review
- Rapid and sensitive electrochemical detection of paracetamol using EuZrOScientific reports · 2025Article
- Assessment and Management of Pain and Fever in Pediatric Patients in the Emergency Setting: A Proposed Flowchart for the Triage Nurse.Children (Basel, Switzerland) · 2025Article
- Improving Online Drug Information: Insights from Quality Evaluation and Pharmaceutical System Design.Healthcare informatics research · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Musculoskeletal pain conditions are age-related, leading contributors to chronic pain and pain-related disability, which are expected to rise with the rapid global population aging. Current medical treatments provide only partial relief. Furthermore, non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are effective in young and otherwise healthy individuals but are often contraindicated in elderly and frail patients. As a result of its favorable safety and tolerability record, paracetamol has long been the most common drug for treating pain. Strikingly, recent reports questioned its therapeutic value and safety. This review aims to present guideline recommendations. Paracetamol has been assessed in different conditions and demonstrated therapeutic efficacy on both acute and chronic pain. It is active as a single agent and is additive or synergistic with NSAIDs and opioids, improving their efficacy and safety. However, a lack of significant efficacy and hepatic toxicity have also been reported. Fast dissolving formulations of paracetamol provide superior and more extended pain relief that is similar to intravenous paracetamol. A dose reduction is recommended in patients with liver disease or malnourished. Genotyping may improve efficacy and safety. Within the current trend toward the minimization of opioid analgesia, it is consistently included in multimodal, non-opioid, or opioid-sparing therapies. Paracetamol is being recommended by guidelines as a first or second-line drug for acute pain and chronic pain, especially for patients with limited therapeutic options and for the elderly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.